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Objective: The D-SPIRIT registry is designed to investigate 
the safety and efficacy of dabigatran etexilate in patients with 
nonvalvular atrial fibrillation (NVAF) and to collect data on out-
comes in clinical practice.
Methods: The D-SPIRIT is a national, prospective, observa-
tional, post-marketing registry involving patients with NVAF 
who have been taking dabigatran etexilate therapy for stroke 
prevention for a minimum of 6 months prior to enrollment. 
The registry will collect and analyze data from routine care, 
enrolling up to 600 patients in 9 centers. Patients will be fol-
lowed up for 2 years to evaluate effectiveness and safety. A 
sample size of 600 subjects is proposed based on the fol-
lowing assumptions; Two-sided significance level of 0.05 
(1-sided significance level of 0.025), ischemic stroke inci-
dence rate of 0.768%–1.111%, hemorrhagic stroke incidence 
rate of 0.109%–0.130%, transient ischemic attack incidence 
rate of 0.722%–0.623%, therapy discontinuation incidence 
rate of 40% at day 730, and duration of enrollment period of 
12 months with non-uniformed enrollment rate. Ethics ap-
proval was given by Dokuz Eylül University Ethics Committee 
of Clinical Research (2014/54) and approved by the Turkish 
Ministry of Health.
Conclusion: Potential results of D-SPIRIT registry will add 
data from clinical practice to those from the RE-LY trial to ex-
pand knowledge of dabigatran etexilate treatment in patients 
with NVAF.
Amaç: D-SPIRIT kayıt çalışması, günlük pratikte, dabigatran 
tedavisi altındaki nonvalvular atriyum fibrilasyonu (NVAF) bu-
lunan olgularda ilacın etkinlik ve güvenilirliğinin değerlendiril-
mesi amacı ile tasarlandı.
Yöntemler: D-SPIRIT, dabigatran tedavisi altında olan 
NVAF’li hastaların değerlendirildiği ulusal, çok merkezli, ileri-
ye dönük, gözlemsel bir veri tabanı kayıt çalışmasıdır. NVAF 
nedenli inmeden korunma amacı ile en az 6 aydır düzenli 
dabigatran tedavisi altındaki olgular hedef popülasyonu oluş-
turmaktadır. Dokuz farklı merkezden 600 NVAF’li olgunun 
araştırmaya alınması planlanmaktadır. Olgular etkinlik ve 
güvenilirliğinin değerlendirmesi amacı ile 2 yıl süre ile izle-
necektir. Örnek büyüklüğü olan 600 katılımcıda şu özellikler 
dikkate alınmıştır: İki taraflı anlamlılık düzeyi 0.005 (tek taraflı 
anlamlılık 0.025); iskemik inme (%0.768–%1.111), hemora-
jik inme (%0.109–%0.130) ve geçici iskemik atak olaylarının 
(%0.722–%0.623) bir yıllık sürede meydana gelme oranları; 
tedaviden ayrılma oranı 730. günde %40 olması; tarama pe-
riyodunun 12 ay süre ile devam etmesi. Yerel etik kurul onayı 
Dokuz Eylül Üniversitesi Klinik Araştırmalar Etik Kurulu’ndan 
alınmış, (2014/54) proje Türkiye İlaç ve Cihaz Kurum Başkan-
lığı tarafından onaylanmıştır.
Sonuç: D-SPIRIT kayıt çalışmasının sonuçları RE-LY ça-
lışmasının sonuçlarına ek NVAF olan hastalarda dabigatran 
eteksilat tedavisi ile ilgili klinik pratiği etkileyecek bilgiler ka-
tacaktır.
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ABSTRACT ÖZET
ORIGINAL ARTICLE
Atrial fibrillation (AF) is the most common sus-tained cardiac arrhythmia, and is increasing in 
incidence and prevalence.[1,2] It occurs in 1–2% of the 
general population.[3] The prevalence in the Europe is 
6 million, and this is expected to double in the next 
50 years.[3] Few studies have been conducted with 
similar prevalence and incidence ratios of AF in the 
Turkish population.[4] Ischemic stroke and systemic 
embolism are major causes of morbidity and mortal-
ity in patients with AF, who have a 5-fold higher risk 
of stroke than those without AF.[3] Up to 15% of all 
strokes are attributable to AF, and strokes in patients 
with AF have worse outcomes and higher mortality 
rates than those in patients without AF.[5] The main 
aim of treatment is to reduce cardiovascular mortal-
ity and morbidity. This can be achieved by preventing 
thromboembolic events, particularly stroke, reducing 
symptoms and improving quality of life, and decreas-
ing number of hospitalization and total mortality. The 
main treatment for stroke prevention in patients with 
AF is anticoagulants. Recent guidelines recommend 
vitamin K antagonist (VKA) for prevention stroke in 
valvular AF, and VKA or non-vitamin K antagonists 
(NOAC) in patients with nonvalvular atrial fibrilla-
tion (NVAF) after risk stratification.[1]
Numerous risk stratification schemes have been 
developed to help predict levels of stroke risk in pa-
tients with AF (low, moderate, or high) and to man-
age them accordingly.[6] The simplest and most widely 
used risk assessment scheme is the CHADS
2
 scoring 
system. This scoring system is derived from criteria 
used in SPAF (Stroke Prevention in Atrial Fibrillation) 
researches: 2 points for a history of stroke or transient 
ischemic attack (TIA) and 1 point for age >75 years, 
history of hypertension, diabetes, or heart failure.[7]
However, the CHADS
2
 system did not include 
many stroke risk factors, and other “modifiers of risk 
of stroke” need to be considered in a comprehensive 
stroke risk assessment.[3] Therefore, the CHADS
2
 scor-
ing system expanded to include other stroke risk fac-
tors and developed into the CHA
2
DS
2
-VASc scoring 
system.[8] In this scheme, congestive heart failure, hy-
pertension, diabetes mellitus, history of vascular dis-
ease, female sex and age 65-74 years are each assigned 
1 point. History of previous stroke or transient isch-
emic attack and age ≥75 years are assigned 2 points. 
VKAs, especially warfarin, have been in use for 
nearly 50 years and have proven effective agents in the 
process of SPAF. In 
a meta-analysis, the 
relative risk reduc-
tion with warfarin 
therapy in all stroke 
has been reported 
as 64% (2-3). In the 
BAFTA study, when 
compared to warfa-
rin, aspirin showed no difference in the risk of major 
bleeding, and warfarin (target INR 2-3) was shown 
to provide 52% relative risk reduction in primary 
endpoint involving a disability causing a fatal stroke, 
intracranial bleeding or clinically significant arterial 
embolism.[9] This finding is compatible with the re-
sults of the WASPO study, which showed significant-
ly more adverse events, including severe bleeding, 
with aspirin when compared with warfarin.[10] How-
ever, VKAs have important limitations, including a 
narrow therapeutic window, an unpredictable dose–
response effect, numerous drug-drug and drug-food 
interactions, and a slow onset and offset of action.[3] 
Warfarin is the most commonly used agent in Turkey 
for SPAF. Efficacy and safety of warfarin is markedly 
influenced by its time-in-therapeutic range (TTR), re-
ferring to the time patients treated with warfarin spend 
having an international normalized prothrombin time 
ratio (INR) within the therapeutic range, which re-
quires regular blood test monitoring. A recent study 
showed very low TTR values in Turkey.[4] With the 
approval of NOACs for SPAF, antithrombotic treat-
ment patterns are changing around the world and in 
Turkey.
In 2010, the first NOAC for stroke prevention in 
patients with AF, dabigatran etexilate (herein after 
dabigatran), was approved by the US Food & Drug 
Administration and is now available in >80 countries. 
Dabigatran is a direct thrombin inhibitor with rapid 
onset and offset of action, limited drug-drug interac-
tions, and no significant drug-food interactions. It can 
be administered without routine anticoagulation moni-
toring.[11] Other NOACs are the factor Xa inhibitors, 
rivaroxaban (first approved in 2011), apixaban (first 
approved in 2012), and edoxaban (first approved in 
2015).[12–15]
The most comprehensive clinical data about dabi-
gatran was obtained from a phase III RE-LY trial.[11] 
The RE-LY trial included 18,113 patients with average 
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CHADS
2
 score of 2.1 and was followed for 2 years.[11] 
In terms of primary outcomes such as stroke and sys-
temic embolism, dabigatran 110 mg was non-inferior 
(1.54%/year) compared with warfarin (1.71%/year), 
while a dose of dabigatran 150 mg (1.11%/year) was 
found to be superior to warfarin.[11] In terms of ma-
jor and fatal bleeding, low-dose dabigatran was found 
less risky than warfarin, while high-dose dabigatran 
was found to have similar risk to warfarin.[11]
In this context, dabigatran is prescribed with in-
creasing frequency for SPAF in Turkey. Dabigatran 
has been available in Turkey in 2 doses (either 150mg 
b.i.d. or 110 mg b.i.d.) and reimbursed since May 
2013 for SPAF with 1 or more risk factors. Although 
efficacy and safety of NOACs have been shown in 
large randomized controlled clinical trials (RCTs) in 
patients with NVAF,[12–15] these trials may not reflect 
real-world clinical settings due to inclusion of selected 
patients. RCTs generally have standardized protocols 
with closer monitoring of patients constituting an ob-
stacle to their implementation in routine clinical prac-
tice. Observational studies and multinational registries 
have been performed to overcome these limitations.
[16–20] However, Turkey has not been included or rep-
resented with only small numbers of patients in these 
registries. Also a post-marketing observational study 
with a prospective design to assess drug safety and ef-
fectiveness has not yet been conducted in our country.
In short, the D-SPIRIT registry is designed to in-
vestigate safety and efficacy of dabigatran etexilate 
in patients with nonvalvular atrial fibrillation and to 
collect data on outcomes in clinical practice.
Rationale, aim, risk-benefit assessment
No study has been conducted in Turkey to assess safe-
ty and effectiveness in real life of dabigatran, which 
has been routinely used as an anticoagulant for 3.5 
years. The most comprehensive data on its effective-
ness and safety were obtained from the RE-LY study, 
in which Turkey was a participant.[11] However, RE-
LY was a phase 3 trial and included important limita-
tions in adapting its results to real life.
The most important of these limitations was the 
fact that the therapeutic window (TTR) in the treat-
ment group using warfarin as active comparator was 
64%.[11] This TTR rate is much higher than the real life 
rate in Turkey, and in warfarin treatment it indicates 
relatively successful anticoagulant therapy.[4] Another 
point in the RE-LY study is that the average age is 
71, with the 80+ age groups constituting a low pro-
portion. However, in real life a significant portion of 
patients with AF are aged 80 and over. This situation 
illustrates the need for assessment of drug efficacy 
and safety in octogenarians. Pharmacogenetic fac-
tors are valid for each drug, and these play a decisive 
role for dabigatran, which is a pro drug. Enzymes that 
play a role in the process of transformation of a drug 
to active metabolite show ethnic differences, which 
may lead to pharmacodynamic variability that should 
not be ignored. This assumption reveals the necessity 
for testing of dabigatran in different ethnic groups. 
A recent pharmacokinetic study in patients who use 
Dabigatran revealed that there is up to 5 times varia-
tion in the level of active metabolite.[21] Moreover, the 
study demonstrated that these differences make sense 
in terms of evaluating efficacy and safety in clinical 
events. The aim of the present study is observation of 
the effectiveness and safety of Dabigatran in NVAF 
in the Turkish population. The primary purpose is ob-
servation and registration of clinical events in real-
life conditions in NVAF patients under treatment with 
Dabigatran. Other purposes are; determination of de-
mographic, clinical profile and risk factors which af-
fect the effectiveness and safety of dabigatran therapy; 
evaluation of patient compliance with anticoagulant 
treatment, and recording of the potential side effects 
of the drug. As in all other observational studies, risk-
benefit assessment of patients, administration of med-
ical treatment, and the management of disease and 
treatment-related clinical events are the responsibility 
of the clinician observing the patient. In this context, 
with the scope of work involving only questionnaire-
based data collection and participation, there will be 
no additional risk brought to those patients participat-
ing. Additional medical diagnoses, treatment or inter-
vention initiatives will not be undertaken. Valuable 
information about disease and the effectiveness and 
safety of treatment with dabigatran in terms of real-
world data are expected from the study.
METHODS
Design
D-SPIRIT is national, multi-center, prospective, ob-
servational registry database, and will evaluate NVAF 
patients under dabigatran treatment. Investigation of 
600 NVAF patients from 9 different centers in the 
Turk Kardiyol Dern Ars224
tion of the participating physicians. This means there 
are no additional risks to patients by participating in 
this registry. No additional medical procedures are re-
quired, over and above those that the patient would 
receive if not enrolled.
To avoid potential bias and allow for projection of 
real-life data in a clear manner, exclusion criteria are 
limited to absence of informed consent, and persistent 
failure by a patient to comply with the protocol and 
study procedures.
Anticoagulation therapy
D-SPIRIT project is an observational project and initi-
ation of anticoagulant treatment, modification of treat-
ment, posology management and discontinuation of 
therapy are not within the scope of work. Management 
of treatment is entirely the responsibility of the clini-
cian. However, in terms of medical ethics, clinicians 
monitoring patients accept responsibility for providing 
feedback to the center, if medically necessary. 
Clinical outcomes
Demographic and clinical characteristics of the pa-
tients and posology of Dabigatran treatment will be 
province of Izmir is planned. There is a single arm, so 
there are not placebo and/or active drug arms. Diag-
nosis of disease, initiation of dabigatran therapy and 
maintenance, management of disease or treatment-
related adverse events and complications are beyond 
the scope of research, and are the responsibility of 
the clinician. However, if they find it necessary, the 
participating physicians accept the responsibility of 
sharing, illness, and/or relating elements of medical 
treatment to the responsible clinician. The goal of the 
research is mirroring real-life data as much as pos-
sible, and for this reason attempts are made to avoid 
factors that could lead to bias. A detailed flow chart 
and visit calendar are shown in Table 1.
Definition of research population
Planned for inclusion in the research project are pa-
tients over 18 years old with NVAF and under dabi-
gatran treatment for at least 6 months. Diagnosis, and 
determination of indications is outside the scope of 
the project and is the responsibility of the clinician 
monitoring the patient. As in any observational study, 
patients will be managed according to local medical 
practice. Choice of treatment is solely at the discre-
Table 1. Detailed flow chart of the D-SPIRIT project and visit calendar
Data Baseline/Screening  Visit 1 Visit 2 Visit 3 Visit 4
 Visit (3±1 month) (6±1 month) (12±2 month) (24±2 month)
Informed consent X    
Inclusion/exclusion X    
Demographic data X    
Lifestyle data X    
Characteristic of NVAF  X  X  
Medical history X    
Comorbidities X X   
Antithrombotic treatment X1 X2 X2 X2 X2
Additional drugs  X X X X X
Clinical outcomes3 X4 X X X X
Serious adverse event (SAE) X4 X X X X
Adverse drug reaction (ADR)  X4 X X X X
Vital signs X4
1Dabigatran posology usage with the goal of stroke prevention.
2Compliance of patient to dabigatran treatment, possible dose change, planned or unplanned interruption of anticoagulation therapy, temporary or perma-
nent discontinuation of anticoagulation therapy leading to presence of a clinical condition. 
3Clinical outcomes are defined in the relevant section.
4Data between beginning of dabigatran therapy and screening visit will be considered as retrospective data.
NVAF: Nonvalvular atrial fibrillation; D-SPIRIT : Dabigatran’s stroke prevention in real life in Turkey.
saved at the screening visit. Compliance with dabi-
gatran therapy during the research period, possible 
changes in dose of treatment and reasons, release of 
treatment and reasons, discontinuation of dabigatran 
treatment and reasons, changing anticoagulant treat-
ment and reasons shall be recorded. Clinical events 
listed below will be evaluated as “clinical outcomes/
events”. 
• Stroke (Hemorrhagic, ischemic, uncertain clas-
sification)
• Transient ischemic attack (TIA)
• Systemic embolism
• Pulmonary embolism
• Myocardial infarction
• Life-threatening bleeding events
• Major bleedings
• All cause death
• Non-vascular death
• Vascular death
• Death of unknown cause.
Statistical method
In statistical analysis, 0.05 will be accepted as the 
level of significance. Patients’ demographic informa-
tion will be summarized according to the type of data 
by descriptive statistics (n, mean, standard deviation, 
minimum, maximum, median, the difference between 
percentiles) or frequency distribution (n and %). Bi-
nary logistic regression will be used to determine fac-
tors related to clinical outcomes at each study visit. 
Each outcome will be evaluated separately with a bi-
nary logistic regression model. In addition to binary 
logistic regression, generalized estimating equation 
(GEE) will be used repeated measure binary data ob-
tained during the study for each clinic outcome sepa-
rately, if appropriate. Disease-free (clinical without 
hardware) survival time will be calculated using the 
Kaplan-Meier method. In the determination of pos-
sible factors, the Cox regression model will be used.
Calculation of sample size
In determination of sample size, the yearly probability 
of occurrence of events (ischemic stroke, hemorrhag-
ic stroke, and transient ischemic attack) have been 
taken into account. Depending on dabigatran dose, 
probability of ischemic stroke is 0.768%–1.111%, 
probability of hemorrhagic stroke is 0.109%–% 
0.130, and probability of transient ischemic attack is 
0.722%–0.623% per annum. In estimating this ratio 
with a confidence limit of 95% and 0.01% error rate, 
it was determined that the study should be completed 
with a minimum of 422 patients. With the drop-out 
rate assumed to be approximately 40%, the minimum 
number to be included in the sample was calculated as 
591. Finally, with consideration of length of the study 
period and eligibility, it was decided to begin work 
with 600 patients.
DISCUSSION
The D-SPIRIT will be the first national, prospec-
tive, observational, post-marketing registry involving 
NVAF patients already taking dabigatran. The prin-
cipal objective of this nationwide cohort study is to 
assess the efficacy and safety in an “everyday clinical 
practice” population of patients with NVAF treated 
with dabigatran in Turkey. The results will inform fu-
ture decisions and enhance understanding of public 
health aspects of this highly prevalent condition.
Observational studies are an effective tool in ob-
serving the course of illness and evaluating treatment 
effectiveness and safety. Observational studies can also 
provide data that supplements data collected in ran-
domized clinical trials, which generally have stricter 
inclusion criteria and structured monitoring schemes. 
With the exception of one small-scale retrospective 
study by Aslan et al., no studies have been done in 
Turkey on assessment of the safety and effectiveness 
of dabigatran in real life.[22] Aslan et al. included 439 
patients and found that ischemic stroke and all-cause 
mortality were lower in the dabigatran group.[22]
The most comprehensive data on the effective-
ness and safety of dabigatran were obtained from the 
RE-LY study, in which Turkey participated.[11] RE-LY 
was a phase-3 trial and there were important limita-
tions in adapting its results to real life. Discrepancy 
between the RE-LY trial and postmarketing studies in 
terms of safety and efficacy outcomes were confirmed 
by some nationwide cohort studies and registries.[16,23] 
Quality of anticoagulation with warfarin, drug adher-
ence, patient demographics (age, female gender), co-
morbidities such as chronic kidney disease, coronary 
artery disease, and heart failure are main reasons for 
discrepancies in outcomes.
One important reason for these discrepancies is the 
TTR value in the treatment group using warfarin as 
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peutic range on outcomes of patients with atrial fibrillation 
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J, Parekh A, et al. Dabigatran versus warfarin in patients with 
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fibrillation. N Engl J Med 2011;365:883–91. CrossRef
13. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek 
EM, Hanna M, et al. Apixaban versus warfarin in patients 
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fibrillation: design and rationale for the Effective aNticoaGu-
lation with factor xA next GEneration in Atrial Fibrillation-
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AF-TIMI 48). Am Heart J 2010;160:635–41. CrossRef
16. Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener 
HC, Dubner SJ, et al. Antithrombotic Treatment Patterns 
active comparator being 64%.[11] This TTR rate is sig-
nificantly higher than in real life in Turkey, and these 
values in warfarin treatment arm indicate relatively 
successful anticoagulant therapy.[4,11] Unlike phase tri-
als which require regular visits and close follow- ups, 
drug adherence may not be sufficiently high in real 
life patients in routine clinical practice. As common 
characteristics of real life patients, polypharmacy and 
elderliness are the main reasons behind poor drug 
compliance. Another point in RE-LY study, that the 
average age is 71 and 80 and over age group repre-
sented in the study is a low proportion. However, 
in real life a significant portion of patients with AF 
aged 80 and over. This situation illustrates the need 
for assessment of drug efficacy and safety in octoge-
narians. Pharmacogenetic factors valid for each drug 
and it have a decisive role for dabigatran, which is a 
pro drug. Enzymes that play a role in the process of 
transformation drug to active metabolite show ethnic 
differences which can lead to pharmacodynamic vari-
ability that should not be ignored. This assumption 
reveals the necessity of dabigatran to be tested in dif-
ferent ethnic groups. A recent pharmacokinetic study 
in patients who use Dabigatran revealed that there is 
up to 5 times variation in the level of active metabo-
lite.[21] Moreover, it has demonstrated that these dif-
ferences make sense in terms of evaluating efficacy 
and safety in clinical events.
Conclusion
The D-SPIRIT registry will provide valuable data for 
clinical practice in Turkey with respect to dabigatran 
management for patients with NVAF.
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